ES2103113T3 - Acido (7s)-7-(2r)-2-(3-clorofenil)-2-hidroxietilamino-5,6,7,8-tetrahidronaftalen-2-iloxi acetico, sus sales farmaceuticamente aceptables, de accion agonista beta3 adrenergica, composiciones farmaceuticas y reactivos de laboratorio que lo contienen. - Google Patents

Acido (7s)-7-(2r)-2-(3-clorofenil)-2-hidroxietilamino-5,6,7,8-tetrahidronaftalen-2-iloxi acetico, sus sales farmaceuticamente aceptables, de accion agonista beta3 adrenergica, composiciones farmaceuticas y reactivos de laboratorio que lo contienen.

Info

Publication number
ES2103113T3
ES2103113T3 ES94401163T ES94401163T ES2103113T3 ES 2103113 T3 ES2103113 T3 ES 2103113T3 ES 94401163 T ES94401163 T ES 94401163T ES 94401163 T ES94401163 T ES 94401163T ES 2103113 T3 ES2103113 T3 ES 2103113T3
Authority
ES
Spain
Prior art keywords
acetico
iloxi
contain
acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94401163T
Other languages
English (en)
Inventor
Marco Baroni
Roberto Cecchi
Tiziano Croci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Application granted granted Critical
Publication of ES2103113T3 publication Critical patent/ES2103113T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL NUEVO COMPUESTO , EL ACIDO(/S)-7 (2R)-2-(3-CLROFENIL)-2-HIDROXIETILAMINO -5,6,7,8TETRAHIDRONAFTALEN-2-ILOXI ACETICO DE FORMULA (I) ASI COMO SUS SALES FARMACEUTICAMENTE ACEPTABLES, DE ACCION BETA 3 AGONISTA ADRENERGICA, LAS COMPOSICIONES FARMACEUTICAS Y LOS REACTIVOS DE LABORATORIO QUE LO CONTIENEN.
ES94401163T 1993-05-28 1994-05-26 Acido (7s)-7-(2r)-2-(3-clorofenil)-2-hidroxietilamino-5,6,7,8-tetrahidronaftalen-2-iloxi acetico, sus sales farmaceuticamente aceptables, de accion agonista beta3 adrenergica, composiciones farmaceuticas y reactivos de laboratorio que lo contienen. Expired - Lifetime ES2103113T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93401375A EP0627407A1 (fr) 1993-05-28 1993-05-28 Acide (7S)-7-[(2R)-2(3-chlorophényl)-2-hydroxyéthylamino]-5,6,7,8-tétrahydronaphtalèn-2-yloxy acétique, ses sels pharmaceutiquement acceptables, à action agoniste bêta-3 adrénergique et compositions pharmaceutiques le contenant

Publications (1)

Publication Number Publication Date
ES2103113T3 true ES2103113T3 (es) 1997-08-16

Family

ID=8214713

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94401163T Expired - Lifetime ES2103113T3 (es) 1993-05-28 1994-05-26 Acido (7s)-7-(2r)-2-(3-clorofenil)-2-hidroxietilamino-5,6,7,8-tetrahidronaftalen-2-iloxi acetico, sus sales farmaceuticamente aceptables, de accion agonista beta3 adrenergica, composiciones farmaceuticas y reactivos de laboratorio que lo contienen.

Country Status (8)

Country Link
US (1) US5488151A (es)
EP (2) EP0627407A1 (es)
JP (1) JP3939369B2 (es)
AT (1) ATE151405T1 (es)
DE (1) DE69402463T2 (es)
DK (1) DK0626367T3 (es)
ES (1) ES2103113T3 (es)
GR (1) GR3023729T3 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0845451A4 (en) * 1995-07-26 1999-10-13 Ono Pharmaceutical Co NAPHTHYLOXYACETIC ACID DERIVATIVES AND MEDICINAL PRODUCTS INTEGRATING THESE DERIVATIVES AS ACTIVE INGREDIENTS
US6197993B1 (en) 1996-07-02 2001-03-06 Ono Pharmaceutical Co., Ltd. Naphthyloxyacetic acid derivatives and a pharmaceutical composition comprising them as an active ingredient
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
PL325865A1 (en) * 1995-09-21 1998-08-17 Lilly Co Eli Selective antagonists of beta3-adrenergic receptor
ATE215369T1 (de) 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
AU8562098A (en) * 1997-08-19 1999-03-08 Kissei Pharmaceutical Co. Ltd. Phenylethanolaminotetralin derivatives and bronchodilators
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
FR2784582B3 (fr) 1998-10-14 2000-11-24 Sanofi Sa Nouvelle utilisation therapeutique de composes a activite beta-3-agoniste
EP1623705A1 (en) * 2004-07-09 2006-02-08 Sanofi-Aventis Use of phenylethanolaminotetralines for preparing anxiolytic drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79323A (en) * 1985-07-10 1990-03-19 Sanofi Sa Phenylethanolaminotetralines,their preparation and pharmaceutical compositions containing them
IT1204416B (it) * 1986-06-27 1989-03-01 Midy Spa Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini
ATE116284T1 (de) * 1987-08-12 1995-01-15 Sanofi Sa Verfahren zur o-alkylierung von n- (hydroxy)aralkylphenylethanolamin.
US5198586A (en) * 1987-08-12 1993-03-30 Sanofi Process for the preparation of phenylethanolaminotetralins
US5235103A (en) * 1987-08-12 1993-08-10 Sanofi Process for the preparation of phenylethanolaminotetralins
US5312961A (en) * 1989-02-14 1994-05-17 Elf Sanofi 2-amino-7-hydroxytetralin carboxylalkyl ethers
IE65511B1 (en) * 1989-12-29 1995-11-01 Sanofi Sa New phenylethanolaminomethyltetralins

Also Published As

Publication number Publication date
GR3023729T3 (en) 1997-09-30
JPH0770013A (ja) 1995-03-14
EP0626367B1 (fr) 1997-04-09
ATE151405T1 (de) 1997-04-15
EP0626367A1 (fr) 1994-11-30
DE69402463T2 (de) 1997-11-27
DE69402463D1 (de) 1997-05-15
US5488151A (en) 1996-01-30
EP0627407A1 (fr) 1994-12-07
DK0626367T3 (da) 1997-10-27
JP3939369B2 (ja) 2007-07-04

Similar Documents

Publication Publication Date Title
AR019365A1 (es) Compuesto de 1-piperidin-3-fenil-butil-naftamida, proceso para prepararlo, composicion farmaceutica y uso para fabricar un medicamento util para eltratamiento de una enfermedad por antagonistas de taquicininas neuropeptidicas endogenas
ES2103113T3 (es) Acido (7s)-7-(2r)-2-(3-clorofenil)-2-hidroxietilamino-5,6,7,8-tetrahidronaftalen-2-iloxi acetico, sus sales farmaceuticamente aceptables, de accion agonista beta3 adrenergica, composiciones farmaceuticas y reactivos de laboratorio que lo contienen.
ES2155844T3 (es) Preparacion de n-alquilcarboxilatos de piperidinilo 3,4,4-trisustituidos e intermedios, utiles como antagonistas de opiaceos.
UY27740A1 (es) Nuevos compuestos
AR038045A1 (es) Agentes terapeuticos
ES2099047T3 (es) Sal de magnesio opticamente pura de un compuesto de piridinilmetilsulfinil-1h-bencimidazol.
PE20000556A1 (es) Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BRPI0410391A (pt) derivados (2-hidróxi-2-(4-hidróxi-3-hidroximetilfenil)-etilamino)- propilfenila como agonistas beta2
ES2052166T3 (es) Derivados de 24-homo-vitamina-d, procedimiento para su preparacion, preparados farmaceuticos que contienen estos derivados asi como su utilizacion como medicamentos.
ES2120145T3 (es) Compuestos bi-aromaticos acetilenados con grupo adamantilo, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
PT775117E (pt) Analogos de 2-nitroimidazole fluorinados para detectar celulas de tumor hipoxicas
BR0016130A (pt) Composto, formulação farmacêutica, e, uso de um composto
ES2046671T3 (es) Un procedimiento para la preparacion de tetrahidroimidazo(1,4)benzodiazepin-2-tionas.
GT200000049A (es) Compuestos quimicos.
AR029795A1 (es) Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
ES2037665T3 (es) Procedimiento para la preparacion de compuestos heterociclicos que contienen n.
ES503884A0 (es) Procedimiento para la preparacion de nitratos de amino-deso-xi-1.4;3.6-dianhidro-hexito,asi como de sus sales de adicionacida farmacologicamente inocuas
Gadekar et al. Some Halogenated 1, 2, 3-Benzotriazin-4 (3H) ones.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
ES8106905A1 (es) Procedimiento para preparar derivados de benzodiazepina
ES8706148A1 (es) Un procedimiento para preparar nuevos derivados de carbapenem.
ES2057341T3 (es) Ciclohexenos substituidos como agentes para el sistema nervioso central.
ES2076037T3 (es) Aminoesteres de los acidos 1,3,5-triacin-2,4,6-tris-alquilaminocarboxilicos, agentes biocidas que los contienen, asi como procedimiento para su fabricacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 626367

Country of ref document: ES